Dx M&A Deals Decline as Industry Returns to Normal Post-COVID Boom
Article By Kelsy Ketchum / January 8, 2024
The diagnostics industry has finally completed its return to normal after three years of heavier dealmaking, as full-company mergers and acquisitions declined to pre-COVID-19 levels in 2023.
Resources
A Shifting Market Environment and Strategies Fueling Innovation in Prostate Cancer Treatment
Blockbuster drug patent expiration, advances in enabling technology, and the emergence of personalized medicine for prostate cancer treatment create a landscape worth examining.
DownloadResources
Outcome Capital Life Science Market Pulse, March 2025
Outcome Capital Life Science Market Pulse March 2025 Click to view our LifeSciences Pulse Newsletter
DownloadContact Us for More Information
Would you like to learn more about working with Outcome Capital or discuss your specific needs?
© Outcome Capital 2025. Member of Financial Industry Regulatory Authority (FINRA) and the Securities Investment Protection Corporation (SIPC). Check the background of this firm on FINRA’s BrokerCheck.
Outcome Capital and Outcome Life Sciences are affiliates of Outcome Holdings, LLC
Business Continuity Plan | Privacy Policy | Regulation Best Interest
